AstraZeneca’s Truqap in combination with Faslodex has been approved in the European Union for the treatment of adult patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA, AKT1, or PTEN-alterations following recurrence or progression on or after an endocrine-based regimen, the company announced.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca reports CAPItello-290 Phase 3 trial did not meet primary endpoints
- AstraZeneca: IMFINZI +chemo gets approval for endometrial cancer with dMMR
- AstraZeneca reports Imfinzi plus chemo approved for endometrial cancer in U.S.
- AstraZeneca announces results from ECHO Phase III trial
- AstraZeneca’s Farxiga approved by FDA to treat pediatric diabetes